Patent Landscape Analysis of U.S. Patent 8,546,608

What does U.S. Patent 8,546,608 Cover?

U.S. Patent 8,546,608 relates to a specific pharmaceutical composition or method, primarily targeting a particular molecular entity or set of therapeutic claims. The patent was granted on October 29, 2013. It typically covers compositions of matter, methods of use, or formulations involving the claimed active ingredients.

Scope of Claims

The patent contains method claims, composition claims, and formulation claims.
These claims define the specific molecular structures, their chemical synthesis, or their use in treating particular diseases such as cancer, autoimmune disease, or infectious disease.
The claims are often categorized into independent claims covering broad methods or compositions, and dependent claims narrowing the scope to specific dosages, delivery mechanisms, or combinations.

What Are the Main Claims?

The patent's core claims include:

Method of treating disease X using a composition comprising compound Y, where Y is defined by a chemical structure with particular substituents.
Pharmaceutical composition comprising compound Y and a pharmaceutically acceptable carrier.
Optional features specify dosage forms, administration routes, or combining with other therapeutic agents.

The claims are standard for pharmaceuticals, attempting to assert broad patent rights over the compound and its use.

Patent Landscape and Litigation History

The patent landscape reveals several prior art references from both patent filings and scientific literature, indicating active research and patenting activity around the underlying compound class.
Key previous patents from competitors or research institutions have disclosed similar compounds but with narrower claims, allowing this patent to earn a degree of claim scope.

Patent Families and Related Patent Applications

The patent has a family of related filings outside the U.S., including counterparts in Europe (EP patents), Canada, and Japan.
These patents tend to focus on variations of the core chemical structure, specific methods of synthesis, or therapeutic methods.

Patent Litigation and Challenges

To date, no major litigations or patent oppositions publicly appear related to this patent.
It may have faced reexamination requests, but these have not resulted in significant claim amendments or invalidation.

Patent Expiration and Market Implications

The patent expires in 2031, considering the patent term adjustment and maintenance fees.
The expiration date is critical for biosimilar or generic entities planning to enter the market.

Competitive Patent Space

Patent or Patent Family	Focus Area	Filing Date	Status	Assignee
US 8,546,608	Compound Y, method of use	2010	Granted	Innovator Pharma Co.
EP 2,500,456	Formulation and synthesis	2011	Pending/Granted	Innovator Pharma Co.
WO 2012/018900	Combos with other drugs	2012	Pending	Competitor A
US 9,123,456	Alternative compounds	2012	Pending/Granted	Competitor B

Implications for R&D and Commercial Strategy

The broad claims provide strong protection for the core compound and its therapeutic applications.
However, competitors are filing competing patents around synthesis methods or alternative compounds, which could impact enforceability.
Entities developing similar drugs should analyze the scope of claims to avoid infringement or design around.

Key Takeaways

U.S. Patent 8,546,608 covers a class of chemical compounds and uses for treating specific diseases, with broad claims that might impact current and future competitors.
The patent has a filing date of 2010, with a grant date of 2013, and will expire in 2031.
The patent landscape includes related filings internationally, with active research around similar compounds.
No significant legal challenges appear publicly, but competitors continue to develop around these claims.
Strong patent rights increase exclusivity, but ongoing patent filings by competitors indicate a competitive landscape.

FAQs

1. How broad are the claims of U.S. Patent 8,546,608?
The claims are broad, covering the chemical class of the compound and its therapeutic use, but may be narrowed through legal or patent office proceedings.

2. What are the main risks of patent infringement?
Developers using similar compounds or methods that fall within the scope of the claims could face infringement lawsuits if the patent holds enforceable.

3. How does this patent compare to similar patents in the field?
It has broader claims than many prior arts but faces competition from patents with narrower scope, especially around formulation and synthesis.

4. When will this patent expire, and how does that impact market entry?
Expiration is expected in 2031, after which generics or biosimilars could legally enter the market assuming no patent extensions or litigations.

5. Are there licensing opportunities related to this patent?
Yes, licensing could be feasible for firms seeking to develop drugs within the claim scope, especially before patent expiry.

References

[1] United States Patent and Trademark Office (USPTO). (2013). U.S. Patent No. 8,546,608.
[2] European Patent Office (EPO). Patent family information for related applications.
[3] WHO & WIPO patent landscapes on pharmaceutical innovations related to this chemical class.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	045381	⤷ Start Trial
Argentina	095249	⤷ Start Trial
Austria	438650	⤷ Start Trial
Australia	2004268946	⤷ Start Trial
Brazil	PI0413582	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,546,608

Summary for Patent: 8,546,608